Clinical trials: Patients With Advanced Solid Tumors
Neoplasm
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
This clinical study evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of dalotuzumab (MK-0646) in participants with relapsed or refractory locally advanced or metastatic solid tumors using once weekly and…
- Trial name
- NCT00694356
- Testing
- Dalotuzumab
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms
OMO-1 in Solid Malignancies
This is a modular, first time in patient, open-label, multicentre study of OMO-1, administered orally, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid…
- Trial name
- NCT03138083
- Testing
- OMO-1
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 40 people
- Sponsor
- Octimet Oncology N.V.
Advanced Solid Tumours
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
This is a phase Ib, open-label, multicentre study of AZD1775 administered orally in monotherapy and in combination with carboplatin and paclitaxel to Asian patients with advanced solid tumours.
- Trial name
- NCT02341456
- Testing
- AZD1775, Paclitaxel, carboplatin
- Where
- 7 sites in Australia, Japan and 1 more
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Advanced Solid Tumors
A Study of BGM-2121 in Patients With Advanced Solid Tumors
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
- Trial name
- NCT07346846
- Testing
- BGM-2121
- Where
- 3 sites in Taiwan
- Volunteers
- 35 people
- Sponsor
- BioGate Precision Medicine Corp.
Cancer (Solid Tumors)
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
The purpose of this clinical research is to assess the safety and tolerability of BMS-690514 when given in combination with paclitaxel and carboplatin.
- Trial name
- NCT00420186
- Testing
- BMS-690514
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Advanced or Metastatic Solid Tumors
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung…
- Trial name
- NCT01928394
- Testing
- Nivolumab, Ipilimumab, Cobimetinib
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 1,163 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of ACR246.
- Trial name
- NCT06238401
- Testing
- ACR246 for injection
- Where
- 6 sites in China
- Volunteers
- 77 people
- Sponsor
- Hangzhou Adcoris Biopharmacy Co., Ltd
Neoplasms
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
- Trial name
- NCT00475956
- Testing
- AZD2171, AZD0530
- Where
- 3 sites in Germany
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Neoplasms
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
The purpose of this study is to support the qualification of a replacement manufacturing site for DOXIL/CAELYX.
- Trial name
- NCT02081495
- Testing
- DOXIL/CAELYX reference product (Treatment A), DOXIL/CAELYX test product (Treatment B)
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Advanced/Metastatic Solid Tumors
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors.
- Trial name
- NCT05277402
- Testing
- ADG116
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adagene Inc
Solid Tumor
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
- Trial name
- NCT04111445
- Testing
- ADG116
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Adagene Inc
Solid Tumors
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
The purpose of this study is to determine whether treatment with necitumumab monotherapy affects the QT/QTc interval among participants with advanced solid tumors refractory to standard treatment or for which no standard…
- Trial name
- NCT01624467
- Testing
- Necitumumab
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
A Study of SKLB1028 in Patients With Advanced Solid Tumor
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SKLB1028 in patients with advanced solid tumors.
- Trial name
- NCT05072522
- Testing
- SKLB1028
- Where
- China
- Volunteers
- 98 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma
- Trial name
- NCT02045602
- Testing
- VCN-01, Gemcitabine, Abraxane®
- Where
- 5 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Theriva Biologics SL
Neoplasms
A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.
This purpose of the study is to determine what dose of JNJ-38877605 is safe and if JNJ-38877605 has any effect in patients with advanced or refractory solid tumors for which there are not alternative therapies.
- Trial name
- NCT00651365
- Testing
- JNJ-38877605
- Volunteers
- 14 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Urinary System Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Phase IIa/IIb clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors such as locally advanced or metastatic urinary system tumors.
- Trial name
- NCT05785039
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
This was an open label, multicenter, Phase 2 study designed to assess the efficacy and safety of tislelizumab in combination with fruquintinib in participants with advanced or metastatic, unresectable gastric cancer (GC), or…
- Trial name
- NCT04716634
- Testing
- Tislelizumab, Fruquintinib
- Where
- 13 sites in China, South Korea
- Volunteers
- 84 people
- Sponsor
- BeiGene
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479…
- Trial name
- NCT01562899
- Testing
- MEK162, AMG 479
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.